These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12627909)

  • 21. Small bladder and multiple urethral recurrences after intravesical instillation of bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.
    Manasia P; Alcaraz A; Cetina A; Alcover J
    J Urol; 2001 Feb; 165(2):529-30. PubMed ID: 11176420
    [No Abstract]   [Full Text] [Related]  

  • 22. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy for bladder carcinoma.
    Marans HY; Bekirov HM
    J Urol; 1987 Jan; 137(1):111-2. PubMed ID: 3795348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.
    Sosnowski JT
    Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653
    [No Abstract]   [Full Text] [Related]  

  • 24. Ocular involvement following Bacillus Calmette-Guerin immunotherapy for bladder carcinoma.
    Cugati S; Gilhotra JS; Lake S; Gordon DL
    Clin Exp Ophthalmol; 2014 Jul; 42(5):494-5. PubMed ID: 24372891
    [No Abstract]   [Full Text] [Related]  

  • 25. Incidental detection of increased (18)F-FDG uptake and its follow-up in patients with granulomatous prostatitis after BCG treatment for urinary bladder cancer.
    Kim CY; Lee SW; Yoon G; Jeong SY; Ahn BC; Lee J
    Hell J Nucl Med; 2014; 17(3):204-7. PubMed ID: 25397626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Reiter syndrome after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy: a case report].
    Shiba M; Fujii T; Takatera H
    Hinyokika Kiyo; 2003 Oct; 49(10):599-601. PubMed ID: 14655604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tubercular disease caused by Bacillus of Calmette-Guérin as a local adjuvant treatment of relapsing bladder carcinoma.
    Manfredi R; Dentale N; Piergentili B; Pultrone C; Brunocilla E
    Cancer Biother Radiopharm; 2009 Oct; 24(5):621-7. PubMed ID: 19877893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes observed in multiparametric prostate magnetic resonance imaging characteristics correlate with histopathological development of chronic granulomatous prostatitis after intravesical Bacillus Calmette-Guerin therapy.
    Logan JK; Walton-Diaz A; Rais-Bahrami S; Merino MJ; Turkbey B; Choyke PL; Pinto PA
    J Comput Assist Tomogr; 2014; 38(2):274-6. PubMed ID: 24637671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Purulent abscess after bacillus Calmette-Guerin therapy for bladder cancer.
    Konrad K; Földes K
    J Rheumatol; 1995 Jul; 22(7):1441. PubMed ID: 7562797
    [No Abstract]   [Full Text] [Related]  

  • 30. Diagnostic and therapeutic technology assessment. Bacillus Calmette-Guerin immunotherapy in bladder cancer.
    JAMA; 1987 Mar; 257(9):1238-40. PubMed ID: 3806925
    [No Abstract]   [Full Text] [Related]  

  • 31. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
    Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
    J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacillus Calmette-Guerin (BCG) balanitis as a complication of intravesical BCG immunotherapy: a case report.
    Erol A; Ozgür S; Tahtali N; Akbay E; Dalva I; Cetin S
    Int Urol Nephrol; 1995; 27(3):307-10. PubMed ID: 7591595
    [No Abstract]   [Full Text] [Related]  

  • 33. The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma.
    Agrawal MS; Agrawal M; Bansal S; Agarwal M; Lavania P; Goyal J
    Urology; 2007 Dec; 70(6):1075-8. PubMed ID: 18158020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re: Agarwal a et al.: The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma (Urology 2007;70:1075-1078).
    Agrawal MS; Bansal S
    Urology; 2009 Feb; 73(2):450-1. PubMed ID: 19185768
    [No Abstract]   [Full Text] [Related]  

  • 35. Bilateral renal masses after local Bacillus Calmette-Guerin therapy for postcystectomy ureteral cancer.
    Squires FB; Coakley FV; Berg WJ; Panicek DM
    Abdom Imaging; 1999; 24(2):200-1. PubMed ID: 10024413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sepsis and granulomatous hepatitis after bacillus Calmette-Guerin intravesical installation.
    Trevenzoli M; Cattelan AM; Marino F; Sasset L; Donà S; Meneghetti F
    J Infect; 2004 May; 48(4):363-4. PubMed ID: 15066339
    [No Abstract]   [Full Text] [Related]  

  • 37. [Cases of bacillus Calmette-Guerin-induced granulomatous prostatitis and prostatic stromal invasion of the bladder carcinoma in situ, showing similar clinical findings].
    Okusa H; Irie A; Chin I; Baba S; Mitomi H; Shitara T
    Hinyokika Kiyo; 2003 Sep; 49(9):555-7. PubMed ID: 14598697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy.
    Dudelzak J; Curtis AR; Sheehan DJ; Lesher JL
    J Drugs Dermatol; 2008 Jul; 7(7):684. PubMed ID: 18664162
    [No Abstract]   [Full Text] [Related]  

  • 39. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer.
    Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ
    South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Miliary tuberculosis after intravesical bacille Calmette-Guérin immunotherapy for carcinoma of the bladder.
    Rabe J; Neff KW; Lehmann KJ; Mechtersheimer U; Georgi M
    AJR Am J Roentgenol; 1999 Mar; 172(3):748-50. PubMed ID: 10063874
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.